NASDAQ
NRSN

Neurosense Therapeutics Ltd

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Neurosense Therapeutics Ltd Stock Price

Vitals

Today's Low:
$0.811
Today's High:
$0.837
Open Price:
$0.833
52W Low:
$0.79
52W High:
$2.91
Prev. Close:
$0.838
Volume:
8473

Company Statistics

Market Cap.:
$12.53 million
Book Value:
-0.113
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-89.39%
Return on Equity TTM:
-368.06%

Company Profile

Neurosense Therapeutics Ltd had its IPO on 2021-12-09 under the ticker symbol NRSN.

The company operates in the Healthcare sector and Biotechnology industry. Neurosense Therapeutics Ltd has a staff strength of 14 employees.

Stock update

Shares of Neurosense Therapeutics Ltd opened at $0.83 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.81 - $0.84, and closed at $0.83.

This is a -1.55% slip from the previous day's closing price.

A total volume of 8,473 shares were traded at the close of the day’s session.

In the last one week, shares of Neurosense Therapeutics Ltd have slipped by -10.42%.

Neurosense Therapeutics Ltd's Key Ratios

Neurosense Therapeutics Ltd has a market cap of $12.53 million, indicating a price to book ratio of 2.3137 and a price to sales ratio of 0.

In the last 12-months Neurosense Therapeutics Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-13798000. The EBITDA ratio measures Neurosense Therapeutics Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Neurosense Therapeutics Ltd’s operating margin was 0% while its return on assets stood at -89.39% with a return of equity of -368.06%.

In Q2, Neurosense Therapeutics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Neurosense Therapeutics Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neurosense Therapeutics Ltd’s profitability.

Neurosense Therapeutics Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.9176. Its price to sales ratio in the trailing 12-months stood at 0.

Neurosense Therapeutics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$7.87 million
Total Liabilities
$3.01 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Neurosense Therapeutics Ltd ended 2024 with $7.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.87 million while shareholder equity stood at $-1545000.00.

Neurosense Therapeutics Ltd ended 2024 with $0 in deferred long-term liabilities, $3.01 million in other current liabilities, in common stock, $-29900000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.09 million and cash and short-term investments were $7.09 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Neurosense Therapeutics Ltd’s total current assets stands at $7.56 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $434000.00 compared to accounts payable of $1.09 million and inventory worth $0.

In 2024, Neurosense Therapeutics Ltd's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Neurosense Therapeutics Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.83
52-Week High
$2.91
52-Week Low
$0.79
Analyst Target Price
$7.25

Neurosense Therapeutics Ltd stock is currently trading at $0.83 per share. It touched a 52-week high of $2.91 and a 52-week low of $2.91. Analysts tracking the stock have a 12-month average target price of $7.25.

Its 50-day moving average was $1.11 and 200-day moving average was $1.53 The short ratio stood at 0.23 indicating a short percent outstanding of 0%.

Around 3688.1% of the company’s stock are held by insiders while 94.4% are held by institutions.

Frequently Asked Questions About Neurosense Therapeutics Ltd

The stock symbol (also called stock or share ticker) of Neurosense Therapeutics Ltd is NRSN

The IPO of Neurosense Therapeutics Ltd took place on 2021-12-09

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$804.6
-32.25
-3.85%
$2.04
0.09
+4.62%
$295.9
-6
-1.99%
$3.26
0.15
+4.82%
$1.6
-0.04
-2.44%
Ascential plc (AIAPF)
$3.35
0.85
+34%
Iqstel Inc (IQST)
$0.2
-0
-1.46%
InPost S.A (INPOY)
$6.26
-0.03
-0.4%
$0.78
0.01
+0.66%
$18.88
0.4
+2.16%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company’s preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Address

Building B, Herzliya, Israel, 4672562